On the treatment of degeneration of the macula and posterior pole
DOI:
https://doi.org/10.31288/oftalmolzh201912328Keywords:
degeneration of the macula and posterior pole, iontophoresis of Omk2Abstract
Background: The field of degeneration of the macula and posterior pole (DMPP) is of outstanding medical and social significance as the disease is of high prevalence and leads to loss of general working capacity.
Purpose: To determine the efficacy of conservative treatment with endonasal iontophoresis of Omk2, and the degree of stabilization of visual functions after this treatment in patients with DMPP.
Materials and Methods: Thirty-two patients (45 eyes; age, 51 to 75 years) with DMPP were examined and received treatment with endonasal iontophoresis of Omk2. The eye examination included visual acuity, retinal light sensitivity, threshold assessment with macula tester, perimetry and ophthalmoscopy, and was performed before and after treatment.
Results: In all patients with DMPP, iontophoresis of Omk2 contributed to apparent improvement in functional activity of the retina, which was achieved due to antioxidative, neurotropic, anti-edema and anti-angiogenetic properties of the drug. In particular, mean uncorrected visual acuity (UCVA) in patients of group 1 improved by 25%, from 0.6 to 0.85, and UCVA in 49% of patients of group 2 improved by 0.01-0.02, which improved the level of social rehabilitation of these patients. In patients with DMPP, the treatment with iontophoresis of Omk2 resulted in improvements in the functional activity of the retinal photopic system and foveal afferent system (as assessed by the Haidinger’s brushes test), and retinal blood flow in the posterior pole (as assessed by the blue field technique) by 33-43%, 14%, and 40%, respectively. This demonstrates that the treatment strategy has the beneficial impact on the function of the visual system, and iontophoresis of Omk2 is a pathogenetically reasonable approach to the management of DMPP.
Conclusion: Iontophoresis of Omk2 was found to be beneficial for the function of the visual system, and a pathogenetically reasonable approach to the management of DMPP.
References
1.Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int. 2009 Feb;54(2):111-8. https://doi.org/10.1016/j.neuint.2008.10.008
2.Weiser MJ, Butt СM, Mohajeri МН. Docosahexaenoic Acid and Cognition throughout the Lifespan. Nutrients. 2016 Feb;8(2): 99.https://doi.org/10.3390/nu8020099
3.Duffy SJ, Vita JA. Effects of phenolics on vascular endothelial function. Curr Opin Lipidol. 2003 Feb;14(1):21-7.https://doi.org/10.1097/00041433-200302000-00005
4.Korol AR, Khramenko NI, Zadorozhnyy OS, Kustryn TB. [Interrelationship of choroidal morphometric characteristics and ocular blood volume in patients with age-related macular degeneration]. Ophthalmol Zh. 2013;(3):23-7. Russian.https://doi.org/10.31288/oftalmolzh201332326
5.McCusker MM, Durrani K, Payette MJ, Suchecki J. An eye on nutrition: The role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. Clin Dermatol. 2016 Mar-Apr;34(2):276-85.https://doi.org/10.1016/j.clindermatol.2015.11.009
6.Parisi V, Centofanti M, Ziccardi L, Tanga L, Michelessi M, Roberti G, Manni G. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1327-40.https://doi.org/10.1007/s00417-015-3044-9
7.Kliushnikov SA. [Neuroprotective and neuroreparative effects of Ceraxon (Citicoline): A review of experimental and clinical studies]. Nervnyie bolezni. 2012; (3):14-8. Russian.
8.Sekades JJ. Citicoline: pharmacological and clinical review. Rev Neurol. 2016 Dec 23;63(S03):S1-S73.https://doi.org/10.33588/rn.63S03.2016508
9.A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian J Ophthalmol. 2014 May;62(5):549-53.https://doi.org/10.4103/0301-4738.133484
10.Scheerer R. Die entoptische Sichtbarkeit der Blutbewegungen im Auge und ihre klinische Bedeutung. Klinisches Monatsblatt Augenheilkunde. 1924;73:67-107.
11.Horváth G, Varju D. Polarized light in animal vision: polarization patterns in nature. Springer; Berlin; New York: 2004.https://doi.org/10.1007/978-3-662-09387-0_3
12.Ashton P, Podder SK, Lee VH. Formulation influence on conjunctival penetration of four beta blockers in the pigmented rabbit: A comparison with corneal penetration. Pharm Res. 1991 Sep;8(9):1166-74.https://doi.org/10.1023/A:1015810619869
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Н. В. Коновалова, Н. И. Храменко, О. В. Гузун, Т. М. Серебрина
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
